CompletedNCT00760695
Dronabinol or placebo for severe anorexia
About this title
Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa
Read the official source — NCT00760695Medication studyAges 18+DenmarkEating disorders
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- OdenseSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateOctober 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 24
- Sponsor
- Odense University Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Denmark
- Age range
- Over 18 Years
- Official registry ID
- NCT00760695
- Official title
Show the full official title
Cannabinoid CB1 Receptor Agonist Treatment in Severe Chronic Anorexia Nervosa
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Odense
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Odense University Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including dronabinol and placebo.
Who was this study for?
Listed age limits: from 18 years.
